George Kaiser Family Foundation Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Key Points

• The George Kaiser Family Foundation acquired 513 shares of Thermo Fisher Scientific Inc., worth approximately $255,000, in the first quarter of the year.
• CEO Marc N. Casper and other executives sold a total of 18,400 shares of the company stock in recent transactions, amounting to over $8 million.
• Analysts have adjusted their price targets for Thermo Fisher, with an average consensus price target of $593.00 and a reported average rating of "Moderate Buy."

George Kaiser Family Foundation acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 513 shares of the medical research company's stock, valued at approximately $255,000.

Several other institutional investors and hedge funds have also bought and sold shares of TMO. GAMMA Investing LLC lifted its stake in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 86.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after buying an additional 1,433,444 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth $532,360,000. Kovitz Investment Group Partners LLC raised its position in shares of Thermo Fisher Scientific by 1,905.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after buying an additional 858,193 shares in the last quarter. Finally, Farallon Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 73.8% in the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after buying an additional 523,800 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.7%

Thermo Fisher Scientific stock traded down $3.4740 during mid-day trading on Wednesday, hitting $494.8160. The company's stock had a trading volume of 2,351,499 shares, compared to its average volume of 2,495,940. The business has a 50 day moving average price of $438.09 and a 200-day moving average price of $458.53. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The stock has a market cap of $186.85 billion, a price-to-earnings ratio of 28.62, a price-to-earnings-growth ratio of 2.60 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 earnings per share. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on TMO shares. UBS Group increased their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Royal Bank Of Canada lowered their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research report on Friday, July 11th. Finally, William Blair began coverage on Thermo Fisher Scientific in a research report on Monday. They set an "outperform" rating on the stock. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Activity

In related news, CEO Marc N. Casper sold 8,000 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $52,340,824.30. This represents a 6.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock valued at $8,345,792 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.